Products & Services
MFG & Quality
Products & Services
Scientific research innovation
Classical findings - Classical innovation - Scientific verification
Cultivating cost and scale advantages with disruptive technologies
YiFan
Pharmaceutical
Yifan is an innovative pharmaceutical enterprise focusing on the health field (securities code 002019, securities abbreviation: Yifan pharmaceutical).
Our vision is to develop innovative drugs with definite clinical values, to help disease-afflicted patients regain health.
Currently, we are focusing on four business areas, i.e., macromolecules, small molecules, synthetic biologics, and special traditional Chinese medicines (TCMs), expanding our product R&D pipelines and innovating drugs for disease treatment to address unmet medical needs; and we are striving to set up an extensive commercial network to facilitate the flow of quality drugs having reliable therapeutic effect across the world to help cure diseases.
Media
Trending Now
-
-
-
Evive Biotech and APOGEPHA announce the launch of Ryzneuta® in Germany, the first oversea market launched under Ryzneuta® 's globalization plan
Evive Biotech (Evive), a global biopharmaceutical company devoted to developing novel biologic therapies and a subsidiary of Yifan Pharmaceutical Co. Ltd., and APOGEPHA Arzneimittel GmbH (APOGEPHA), a Dresden based specialty pharmaceutical company, with a strong focus on innovative therapies announce that the new drug Ryzneuta® is now available in the German market on 7th October 2024. This milestone allows patients under chemotherapy in Germany to receive the first non-pegylated long-acting G-CSF product Ryzneuta®.
21/11/2024
-
-
-
-
Ryzneuta™, Evive Biotech’s first biologic product，approved by China’s NMPA
10/05/2023
-
-
-
-
Yifan Pharmaceutical Featured in the 2022 Top 100 List of Chinese Pharmaceutical Innovative Enterprises (CPIE 100)
11/12/2022
-
